• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Anika Announces Third Quarter 2024 Results Conference Call Date

    10/17/24 4:01:10 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care
    Get the next $ANIK alert in real time by email

    BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.

    The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 31842. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion.

    About Anika

    Anika Therapeutics, Inc. (NASDAQ:ANIK) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika's global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

    ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.

    For Investor Inquiries:

    Anika Therapeutics, Inc.

    Matt Hall, 781-457-9554

    Director, Corporate Development and Investor Relations

    [email protected]



    Primary Logo

    Get the next $ANIK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What date will Anika Therapeutics release its third quarter 2024 financial results?

      Anika Therapeutics, Inc. will release its third quarter 2024 financial results before the market opens.

    • When will the conference call discussing Anika's third quarter results take place?

      The results will be discussed during a conference call at 8:30 a.m. ET on October 31, 2024.

    • How can investors access the conference call for Anika's financial results?

      The conference call can be accessed by calling 1-800-717-1738 for domestic calls, or 1-646-307-1865 for international calls.

    • What are the main areas of focus for Anika Therapeutics?

      Anika Therapeutics focuses on joint preservation and early intervention orthopedic care, particularly in areas like osteoarthritis pain management.

    • Will the conference call be available for listening after it has concluded?

      The call will be archived and made available on Anika's Investor Relations section on their website shortly after the conclusion of the call.

    Recent Analyst Ratings for
    $ANIK

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    B. Riley Securities
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    10/14/2022$26.00Equal-Weight
    Stephens
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    3/9/2022Overweight → Equal-Weight
    Stephens & Co.
    More analyst ratings